Organovo (ONVO) Enters Multi-Year Research Collaboration Agreement with Merck (MRK)

April 22, 2015 8:09 AM EDT
Get Alerts ONVO Hot Sheet
Price: $7.03 -2.23%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

On April 17, 2015, Organovo (NYSE: ONVO) entered into a multi-year research collaboration agreement with Merck Sharp & Dohme Corp. (NYSE: MRK). The Agreement will give Merck access to Organovo’s commercial exVive3DTM Human Liver Tissue service, and will also involve a collaboration to develop multiple custom tissue models utilizing the Company’s proprietary NovoGen Bioprinting PlatformTM, for use in drug development.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Momentum Movers, Short Sales